https://www.cytodyn.com/investors/investor-faqs
2026 objectives:
Continue the Phase 2 (CLOVER) study of leronlimab in patients with relapsed/refractory micro-satellite stable colorectal cancer;
Conduct additional studies exploring leronlimab and its therapeutic potential in other solid-tumor oncology indications, including but not limited to metastatic Triple-Negative Breast Cancer; and
Continue our work researching and developing a new or modified long-acting version of leronlimab.